Graham Capital Management, L.P. Protagonist Therapeutics, Inc Transaction History

Graham Capital Management, L.P.

  • $4.42 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$24.66 - $34.8 $262,333 - $370,202
-10,638 Reduced 58.41%
7,574 $262,000
Q1 2024

May 15, 2024
BUY
$21.79 - $32.15 $396,839 - $585,515
18,212 New
18,212 $526,000
Q3 2022

Nov 14, 2022
BUY
$7.86 - $11.71 $420,061 - $625,817
53,443 New
53,443 $450,000

Others Institutions Holding PTGX

# of Institutions
247
Shares Held
56.4M
Call Options Held
76.3K
Put Options Held
114K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email